Core Viewpoint - Merck has received approval from the National Medical Products Administration (NMPA) in China for its novel non-nucleoside cytomegalovirus (CMV) inhibitor, Prevymis® (Letermovir), in two formulations: oral tablets and injectable solution, for use in pediatric patients aged 6 months and older weighing at least 6 kg [1] Group 1 - The approved indications include prevention of CMV infection and disease in adult and pediatric recipients of allogeneic hematopoietic stem cell transplantation (HSCT) who are CMV seropositive [1]